State-of-the-Art Cancer Immunotherapy for Solid Tumors and Future Perspectives

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 581

Special Issue Editors


E-Mail Website
Guest Editor
Department of Immuno-Oncology, First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China
Interests: cancer immunotherapy; pharmacology; anticancer drugs; natural compounds; NSAIDs

E-Mail Website
Guest Editor
School of Life Science, Faculty of Science, University of Technology Sydney, P.O. Box 123, Broadway, NSW 2007, Australia
Interests: cancer; immunotherapy; endocrine resistance; chemotherapy resistance; cell cycle; tumor accelerators; tumor inhibitors

Special Issue Information

Dear Colleagues,

Immunotherapy, such as adoptive T-cell therapy and immune checkpoint blockade, has radically changed the landscape of cancer treatment and provides new hope and treatment options for cancer patients. Clinically, immunotherapy has joined the ranks of surgery, radiation, and chemotherapy as a pillar of cancer therapy. Despite achieving remarkable results in the treatment of hematological malignancies, this remains an enormous challenge in the treatment of solid tumors using immunotherapy. Therefore, it is important to support and encourage active research in cancer immunotherapy and to update and communicate the novel findings in this area effectively.

This Special Issue will highlight the current state of the art and future perspectives in cancer treatment with immunotherapy and combined therapies involving immunotherapy. We look forward to publishing the latest top-quality updates in the emerging area of cancer immunotherapy research and clinical practice. We will accept reviews, original articles, and case reports with a focus on, but not limited to, basic, translational, or clinical research on the applications of CAR-T, TILs, NK, stem cells, immune checkpoint inhibitors, and combination therapy involving immunotherapy in the treatment of solid tumors. Key future perspectives on cancer immunotherapy are also welcome.

Dr. Yiguang Lin
Dr. Eileen McGowan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • cancer adoptive T-cell therapy
  • CAR-T cells
  • immune checkpoint blockade
  • cell-based immunotherapy
  • solid tumors
  • immunotherapy combinations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop